Aclaris Therapeutics, Inc. (ACRS) is a publicly traded Healthcare sector company. As of May 21, 2026, ACRS trades at $4.53 with a market cap of $614.52M and a P/E ratio of -7.97. ACRS moved +1.80% today. Year to date, ACRS is +70.94%; over the trailing twelve months it is +235.56%. Its 52-week range spans $1.05 to $5.17. Analyst consensus is strong buy with an average price target of $10.38. Rallies surfaces ACRS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Aclaris Therapeutics, Inc. (ACRS) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. ACRS moved +1.80% today. Analyst consensus is strong buy.
| Metric | Value |
|---|---|
| Price | $4.53 |
| Market Cap | $614.52M |
| P/E Ratio | -7.97 |
| EPS | $-0.56 |
| Dividend Yield | 0.00% |
| 52-Week High | $5.17 |
| 52-Week Low | $1.05 |
| Volume | 904.18K |
| Avg Volume | 0 |
| Revenue (TTM) | $8.37M |
| Net Income | $-69.66M |
| Gross Margin | 76.34% |
8 analysts cover ACRS: 0 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $10.38.